Bayer
Top Ten most popular articles on Pharmafile.com this week
January 12, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, HIV, J&J, JJ, Johnson & Johnson, Pfizer, Shire, Teva, Xarelto, patient reported outcomes
The Xmas break is now a distant memory as we move further into January, and with another Friday comes another …
Bayer and J&J successfully reverse $28 million Xarelto court payout
January 10, 2018Research and Development, Sales and Marketing Bayer, J&J, JJ, Johnson & Johnson, Xarelto, pharma
Bayer and Johnson & Johnson have managed to avert a payout of $27.8 million after a Pennsylvania state court judge …
Pharma carousel sees Bayer discovery chief head to Shire
December 1, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Shire, biotech, drugs, pharma, pharmaceutical
It’s no secret that when individuals leave companies within the pharma industry, they tend to pop up at a rival …
Bayer’s $175 million pneumonia drug fails at phase 3
November 27, 2017Research and Development, Sales and Marketing Amikacin, Amikacin Inhale, Bayer, Nektar Therapeutics, pharma
Bayer has been hit by the news that its latest effort in the pneumonia space failed at the Phase 3 …
NICE gives final draft guidance on two key cancer drugs
October 12, 2017Sales and Marketing Bayer, CDF, Cancer, Cancer Drugs Fund, Erivedge, NICE, Roche, Stivarga
NICE has announced it has published its final draft guidance for two cancer treatments, covering Bayer’s Stivarga (regorafenib) in the …
Bayer forced to halt huge study into key drug
October 6, 2017Medical Communications, Research and Development Bayer, Janssen, Xarelto, biotech, drugs, pharma, pharmaceutical
Bayer, and development partner Janssen, have been forced to stop a Phase 3 trial looking at expanding the indication of …
NICE recommends Bayer’s Eylea for myopic chorodial neovascularisation
September 22, 2017Medical Communications, Sales and Marketing Bayer, Eylea, NICE, pharma, pharmaceutical
Bayer has revealed that UK drug regulator NICE has given its final recommendation on blockbuster eye drug Eylea (aflibercept solution …
Bayer pulls plug on sterilisation device after numerous complaints
September 21, 2017Sales and Marketing Bayer, Essure, biotech, drugs, pharma, pharmaceutical
Bayer has stopped the commercial sale of a sterilisation device in all countries, except the US, after reports that it …
Bayer lymphoma treatment speeds to FDA approval
September 18, 2017Sales and Marketing Aliqopa, Bayer, biotech, drugs, pharma, pharmaceutical
The FDA gave Bayer priority review for its treatment Aliqopa (copanlisib) in May of this year, and it quickly came …
Casebia Therapeutics bolsters leadership by bringing in two new faces
September 8, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, CRISPR Therapeutics, Casebia Therapeutics, biotech, drugs, pharma, pharmaceutical
Casebia therapeutics, a joint venture between Bayer and CRISPR Therapeutics, has moved to strengthen its leadership team by bringing in …
Bayer’s liver cancer drug availability spreads to UK with NICE approval
August 10, 2017Sales and Marketing Bayer, Cancer, NICE, Nexavar, life sciences, liver cancer, pharma, pharmaceutical
NICE has announced that it has given final appraisal recommending Bayer’s Nexavar (sorafenib) for the treatment of advanced hepatocellular carcinoma …
Bayer secures one-two treatment for liver cancer after EU approval
August 7, 2017Sales and Marketing Bayer, biotech, drugs, pharma, pharmaceutical
Bayer has announced that it has received European Commission approval for its treatment of hepatocellular carcinoma, a type of liver …
Bayer celebrates FDA priority review for investigational blood cancer drug
May 17, 2017Research and Development, Sales and Marketing Bayer, FDA, blood cancer
Bayer has announced that its investigational blood cancer treatment copanlisib has been awarded priority review designation from the FDA, meaning …
FDA approves first new drug for liver cancer in decade
April 28, 2017Medical Communications, Sales and Marketing Bayer, Stivarga, hepatocellular carcinoma, liver cancer
The FDA has announced that it has approved the first new treatment for hepatocellular carcinoma (HCC), a type of liver …
Pregnancy test pill used through 60s & 70s connected with birth defects
March 20, 2017Medical Communications, Sales and Marketing Bayer, Primodos
A pregnancy test, named Primodos, which was taken by 1.5 million British mothers and was linked to birth defects, may …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
